A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Drug Therapy, Combination, HIV Protease Inhibitors, Ritonavir, Indinavir, Saquinavir, Reverse Transcriptase Inhibitors, Viral Load, Nelfinavir
Eligibility Criteria
Inclusion Criteria You may be eligible for this study if you: Are HIV-positive. Have an HIV RNA count of at least 400 copies/ml. Are at least 13 years old (need consent if under 18). Have been on antiretroviral treatment (including at least 2 NRTIs) for at least 16 weeks prior to study entry. Agree to practice abstinence or to use effective methods of birth control, including a barrier method, during the study. Exclusion Criteria You will not be eligible for this study if you: Are pregnant or breast-feeding. Have active opportunistic (HIV-associated) infections. Have taken nelfinavir (NFV) for more than 2 weeks after failing indinavir/ritonavir (IDV/RTV) treatment or have taken IDV/RTV for more than 2 weeks after failing NFV treatment. Have used any protease inhibitor other than NFV or IDV/RTV for more than 2 weeks. Have used any non-nucleoside reverse transcriptase inhibitor (NNRTI) for more than 1 week.
Sites / Locations
- Community Consortium / UCSF
- Denver CPCRA / Denver Public Hlth
- Washington Reg AIDS Prog / Dept of Infect Dis
- AIDS Research Consortium of Atlanta
- AIDS Research Alliance - Chicago
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
- Wayne State Univ - WSU/DMC / Univ Hlth Ctr
- Henry Ford Hosp
- Southern New Jersey AIDS Cln Trials / Dept of Med
- North Jersey Community Research Initiative
- Partners in Research / New Mexico
- Harlem AIDS Treatment Grp / Harlem Hosp Ctr
- The Research and Education Group
- Philadelphia FIGHT
- Richmond AIDS Consortium / Div of Infect Diseases